Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.

Lindsey M Fovel Robert W SeaburyChristopher D MillerWilliam DarkoLuke A ProbstLara Horvath

Published in: Journal of pharmacy practice (2019)

The frequency of VTE recurrence was similar between DOACs and LMWH in patients with cancer. DOACs may be an alternative agent to LMWH for the prevention of recurrent VTE in patients with cancer.

Keyphrases

venous thromboembolism
direct oral anticoagulants
free survival
stem cells
bone marrow
mesenchymal stem cells
smoking cessation